Mayo Clinic Pharmacy Grand Rounds

Life in the Fast Lane: Aducanumab and the Accelerated FDA Approval Process

Joseph C. Osborne II, PharmD, @JOzempic describes the pharmacology of aducanumab, summarizes the clinical literature and approval process for aducanumab, and discusses stewardship considerations of aducanumab. 

Twitter: @JOzempic

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Don’t Be Sad, Be Fab! The Use of Antivenom for Management and Stabilization of Crotalidae Snakebites

Megan L. Grochowski, PharmD, reviews the incidence of common Crotalidae snake envenomation in the United States, describes the progression of signs and symptoms associated with snakebites, explains the role, use, and administration of antivenom in snakebites, and reviews other interventional therapies utilized in the management and stabilization of snakebites.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Renin-Angiotensin System: Should We Give It More Attention in Shock?

Patrick M. Wieruszewski, PharmD, BCCCP, describes the mechanisms of the renin-angiotensin system and its interplay in vasodilatory shock, reviews emerging data surrounding the use of angiotensin II in vasodilatory shock and identifies clinical shock scenarios where angiotensin II may be of most benefit. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

NMS What A Mess!

Mohammad B. Najib, Pharm.D., BCPS, describes the pathophysiology of Neuroleptic Malignant Syndrome (NMS), lists risk factors involved in the disease process, identifies the diagnostic criteria and an overview of the signs and symptoms, and examines management and treatment options. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Management of Guillain-Barré Syndrome

Rachel J. Johnson, Pharm.D., recalls common symptoms of Guillain-Barré Syndrome, describes the association between COVID-19 vaccines and Guillain-Barré Syndrome, and identifies appropriate treatment for a patient with Guillain-Barré Syndrome.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Overcoming the COV-BARRIER: The Role of Baricitinib in SARS-CoV-2

Aeryana N. Beaudrie-Nunn, Pharm.D. (@ABeaudrieRx), identifies the rationale for immunodulatory therapy in COVID-19, explores clinical trial data regarding the use of Baricitinib in hospitalized patients with COVID-19, and defines the patient context where Baricitinib use is most appropriate. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Shocking Updates in the Management of Cardiogenic Shock

Andrew J. Jatis, Pharm.D. (@jatis_rx), recognizes the clinical heterogeneity of cardiogenic shock and its impact on clinical outcomes, describes current literature assessing vasopressors and inotropes in the management of cardiogenic shock, and determines an optimal pharmacologic regimen for the treatment of cardiogenic shock given individual patient characteristics. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

The Migration Medication Situation: Pharmacotherapy Consideration in Refugee Populations

Jennifer M. Nelson, Pharm.D., outlines Center for Disease Control and Prevention (CDC) guidelines for initial care of refugee populations, recognizes unique disease states, genetics, and cultural considerations for the Afghan refugee population, and identifies treatment for unique disease states in the Afghan refugee population. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Sacubitril/Valsartan: Heart Failure’s Worst Nightmare

Robert J. Schroeder, Pharm.D., explains the pharmacological principles of sacubitril/valsartan, recognizes the evidence favoring sacubitril/valsartan in heart failure and describes how to initiate sacubitril/valsartan. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Continuous Glucose Monitors & GMI: Is this TMI?

Katelyn (Kate) R. Neverman, Pharm.D., identifies three continuous glucose monitors (CGMs) approved by the FDA, describes the difference between glucose management indicator (GMI) and hemoglobin A1c and discusses how to interpret glycemic data using an Ambulatory Glycemic Profile (AGP) report. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.